BIOMARKER:

ARID1A mutation

Entrez ID:

Related biomarkers:

‹

›

ARID1A mutation ARID1A mutation	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: B - Late Trials
ARID1A mutation ARID1A mutation	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials
ARID1A mutation ARID1A mutation	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Gastric Cancer Gastric Cancer	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Gastrointestinal Cancer Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Head and Neck Cancer Head and Neck Cancer	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Breast Cancer Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Endometrial Cancer Endometrial Cancer	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Colorectal Cancer CRC	cetuximab Resistant: D – Preclinical
ARID1A mutation ARID1A mutation	Ovarian Cancer Ovarian Cancer	GSK2816126 Sensitive: D – Preclinical
ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	GSK2816126 Sensitive: D – Preclinical
ARID1A mutation ARID1A mutation	Gastric Cancer Gastric Cancer	EZH2 inhibitor Sensitive: D – Preclinical